The Aging Immune System
One of the most significant consequences of aging is immune system decline — a process called immunosenescence. The thymus gland, which produces T-cells (critical immune fighters), begins shrinking after puberty and is largely atrophied by age 50. This leads to reduced immune surveillance, increased susceptibility to infections, slower recovery, and paradoxically, increased autoimmune activity and chronic inflammation.
Peptide therapy offers targeted tools to address specific aspects of immune dysfunction.
Key Peptides for Immune Support
Thymosin Alpha-1
Originally isolated from the thymus gland, Thymosin Alpha-1 is one of the most well-studied immune-modulating peptides. It enhances the function of dendritic cells (which present antigens to the immune system), increases T-cell production and maturation, and modulates the balance between Th1 and Th2 immune responses. It has been approved in over 30 countries for hepatitis B and C treatment and is used clinically for immune support in cancer patients.
Dosing: 1.6 mg subcutaneous injection, 2-3 times per week
BPC-157
While primarily known for tissue healing, BPC-157 has significant immune-modulating properties. It reduces excessive inflammatory responses (particularly TNF-alpha and IL-6), promotes gut immune function (where 70% of the immune system resides), and supports the integrity of the intestinal barrier — preventing immune activation from gut-derived endotoxins.
Dosing: 250-500 mcg/day, subcutaneous or oral
Thymulin (Thymic Factor)
Thymulin is a zinc-dependent peptide naturally produced by the thymus. It promotes T-cell differentiation and maturation, enhances NK (natural killer) cell activity, and helps regulate the inflammatory response. Supplementation may partially compensate for age-related thymic atrophy.
LL-37
An antimicrobial peptide that serves as a first-line immune defense. LL-37 directly kills bacteria, viruses, and fungi while also modulating the inflammatory response to prevent excessive tissue damage during infection.
Low-Dose GLP-1 Agonists
An often-overlooked benefit of GLP-1 receptor agonists like Tirzepatide and Retatrutide is their anti-inflammatory effect on the immune system. GLP-1 receptors are expressed on immune cells, and their activation reduces the production of pro-inflammatory cytokines. At low doses (1-2.5 mg/week Tirzepatide or 1-2 mg/week Retatrutide), these compounds can help calm chronic low-grade inflammation without suppressing necessary immune responses.
Building an Immune Optimization Stack
Foundation: Thymosin Alpha-1 (1.6 mg, 2x/week) + BPC-157 (250 mcg/day)
Enhanced: Add low-dose GLP-1 agonist for systemic inflammation reduction + NAD+ precursor (NMN 500mg/day) for immune cell energy metabolism
Comprehensive: Foundation + Enhanced + Vitamin D (5000-10000 IU/day), Zinc (30mg/day), Vitamin C (1-2g/day), and adequate protein intake for immune cell production
The combination of targeted peptides with nutritional optimization creates a comprehensive approach to immune health that addresses both the age-related decline in immune function and the chronic inflammation that drives disease.